The in vitro antibacterial activity of E-3846, a new fluoroquinolone carboxylic acid derivative with a pyrrol ring substituent at position 7, was evaluated in comparison with norfloxacin and ciprofloxacin. E-3846 was more active than the reference quinolones against Staphylococcus species, including methicillin-resistant strains. E-3846 was similar to ciprofloxacin and more active than norfloxacin against Streptococcus (Enterococcus) faecalis. In general, E-3846 was more active than norfloxacin against members of the family Enterobacteriaceae, but less active than ciprofloxacin. For Pseudomonas aeruginosa, the MICs giving 90% inhibition for E-3846, norfloxacin, and ciprofloxacin were 2, 1, and 0.25 ,ug/ml, respectively. The activity of E-3846 increased at acid pH; in contrast, acid pH caused a pronounced decrease in the activity of norfioxacin and ciprofloxacin. In vivo, E-3846 demonstrated excellent therapeutic efficacy in treating experimental S. faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa cystitis and pyelonephritis in rats.
.
E-3846 (6-fluoro-1-cyclopropyl-1,4-dihydro-4-oxo-7[pyrrol-1-yl]-quinolone-3-carboxylic acid [ Fig. 1] ) is a new fluoroquinolone antibacterial agent with a pyrrol ring at position 7 of the molecule. Other compounds with a 7-pyrrol ring substituent are irloxacin (17) and E-3604 (29) .
In this report, we describe E-3846 and compare its in vitro antibacterial activity with those of norfloxacin and ciprofloxacin against a wide variety of organisms. We also examined the in vivo efficacy of E-3846 in the treatment of experimental urinary tract infections in rats.
MATERIALS AND METHODS Antibacterial agents. E-3846 was synthesized at the Esteve S.A. Laboratories (Barcelona, Spain). Norfloxacin was obtained from Merck Sharp & Dohme (Rahway, N.J.), and ciprofloxacin was provided by Bayer A.G. (Wuppertal, Federal Republic of Germany). Antibacterial agent activities are expressed as micrograms of base per milliliter, and the antibiotic doses are shown as milligrams of base per kilogram.
Bacterial strains. The bacteria used in the first phase of this study were unique recent clinical isolates (only one isolate per patient) obtained from four geographically separate medical centers. The species represented in this collection are listed in Table 1 . The effect of pH on the in vitro inhibitory activity of the antibacterial agents was studied with the following organisms: Staphylococcus aureus ATCC 5488/23, Streptococcus (Enterococcus) faecalis ATCC 10541, Escherichia coli ATCC 10536, Proteus mirabilis ATCC 4675, and Pseudomonas aeruginosa 25115. In the experimental urinary tract infections, five additional strains were used: Streptococcus faecalis U-8158; E. coli 24/16; Proteus mirabilis V-2835 and Pseudomonas aeruginosa S-1209, recently isolated from infected urine; and Klebsiella pneumoniae K66/01, obtained from a laboratory stock culture used in previous studies.
In vitro studies. Growth-inhibitory activity was determined on solid or liquid medium by the antibiotic dilution technique. For the isolates listed in Table 1 , comparative MICs were determined by the agar dilution method (28) . Mueller-Hinton (MH) agar (Oxoid Ltd., London, England) was used for all testing except for Streptococcus faecalis, for which brain heart infusion agar (Oxoid) was used. To determine the MICs for the strains used to produce experimental urinary tract infections, inocula were prepared from overnight broth culture, diluted appropriately to 106 CFU/ml, and inoculated into serial twofold dilutions of E-3846 in MH broth. Subcultures were made for confirmation of purity and for quantitation of the inoculum sizes. The MICs in liquid medium were defined as the lowest concentration of antibacterial agent that inhibited development of visible growth in broth. MBCs were determined by quantitative subculture of 0.1 ml of broth from the control tube, the first tube containing growth, and from all tubes without visible growth on drug-free MH agar plates. The MBCs were defined as the lowest drug concentrations that killed .99.9%o of the initial inoculum.
Urinary tract infections in rats. The bacterial strains used to establish infection were grown overnight on tryptic soy agar (Oxoid) and suspended in physiological saline solution (PSS) to the appropriate concentration. In each experiment, 40 female Wistar rats of strain CFHB (Interfauna U. K., Ltd., Huntington, England) weighing 200 to 250 g were used. Thirty animals were infected, and 10 were used as controls.
Under ether anesthesia (19) , the rats were forced to void urine by gentle compression of the bladder through the external abdominal wall. A 1-ml portion of the bacterial suspension was immediately inoculated transurethrally into the bladder by using a sterile cannula (1.2 by 4.5 mm; Vasocan; B. Braun Melsurgen A.G.). In the control animals, sterile PSS replaced the bacterial suspension. After the inoculation, the external urethral meatus was blocked for 15 min by clamping to facilitate the ascent of the organisms from the bladder to the kidneys. The clamp was then removed, and the rats were kept in individual cages.
(i) Quantitation of infection level. A group of 10 rats was sacrificed 48 h postinfection (pretreatment control group), together with 5 control animals. The organs were removed and weighed under aseptic conditions. The bladder was rinsed with sterile PSS to remove any trace of urine. Afterwards, the bladder and each kidney were homogenized separately, serially 10-fold diluted in Ringer 1/4 solution, and cultured in duplicate on tryptic soy agar plates. The plates were incubated at 37°C for 18 to 20 h. When it was possible to obtain a sufficient quantity of urine, the samples were collected intraurethrally with a syringe and were cultured quantitatively as described above. Bacterial count was expressed as log1o CFU per gram of organ or log1o CFU per milliliter of urine. The lowest number of organisms detectable by this method was 50 CFU. The percentage of organs and urine samples infected, the mean of the log1o CFU, and the standard deviation of the mean of the positive cultures in 10 infected rats were calculated and accepted as the level of infection before treatment.
(ii) Treatment. Antibacterial therapy was started 2 days postinfection; a group of 10 rats was treated for 7 days with a single daily dose of E-3846. Experimental doses of 100 mg/kg in 1 ml of a 0.1% suspension of carboxymethyl cellulose were administered orally. Ten rats infected but left untreated were used as controls for the infection (posttreatment control group).
(iii) Determination of therapeutic efficacy. After 7 days of treatment and at least 18 h after administration of the last dose of antibacterial agent, the bladder, kidneys, and urine samples of treated and untreated rats, together with those from five animals inoculated with PSS, were cultured quantitatively as described above. Table 3 . None of the 10 healthy control rats inoculated with PSS in each experiment showed any bacterial growth in the kidneys, bladder, or urine.
The results indicate that practically all the animals developed urinary tract infection within 2 days of infection (pretreatment control groups) and that levels of infection in the untreated rats were maintained 9 days after inoculation (posttreatment control groups). However, a significant decrease fourth or fewer of the kidneys and from fewer than one-third of the bladders studied, with the exception of Proteus mirabilis V-2835, which was recovered from a larger number of organs. In the groups infected with E. coli 24/16, K. pneumoniae K66/O1, or Proteus mirabilis V-2835, there was also a quantitative decrease in the bacteria recovered from the organs of the treated rats in comparison with those from posttreatment control groups (Table 3) .
The number of urine samples studied and the percentage of positive cultures are shown in Table 3 . The relationship between the presence of bacteria in the urine and the existence of renal infection was absolute: all the rats with positive urine cultures showed renal infection. DISCUSSION E-3846 is a new synthetic fluoroquinolone with a potent broad-spectrum antibacterial activity. It is distinguished from other new agents such as norfloxacin and ciprofloxacin in that it contains a pyrrol ring instead of a piperazine ring at position 7 of the molecule (Fig. 1 ). E-3846 differs from the reference drugs in that it is approximately 32 to 64 times more active than norfloxacin and 8 to 32 times more active than ciprofloxacin against the common Staphylococcus spe- Methicillin-resistant isolates of staphylococci were just as susceptible to E-3846 as the methicillin-susceptible isolates were (Table 1) . In this study, the activity of E-3846 against most members of the family Enterobacteriaceae was superior to or of the same order of magnitude as the activity of norfloxacin and generally inferior to that of ciprofloxacin. Norfloxacin and ciprofloxacin were significantly more active against members of the Enterobacteriaceae than against Staphylococcus and Streptococcus species. Similar findings have been reported by other authors (1, 2, 21 ). E-3846 showed greater activity at acid pH, in contrast to norfloxacin and ciprofloxacin. The activity of norfloxacin and ciprofloxacin has been reported to be lowered by a decreasing pH (2, 7, 26) . Among the fluoroquinolones studied, E-3846 was the most active at pH 4.8 against all tested gram-positive and gram-negative bacteria (Fig. 2) . Other fluoroquinolones with a pyrrol ring substituent at position 7, irloxacin and E-3604, also show major activity at acid pH values (5, 29) . It is possible that the pyrrol ring contributes to the excellent antibacterial activity of these compounds at acid pH. In general, the effect of pH should be considered when treating infections at sites where the pH may not be neutral. Since the pHs at many infections sites, such as abscesses, urinary tract, gall bladder, and prostate, are acidic, the activity of E-3846 may be greater in vivo than expected based simply on MICs. Thus, E-3846 would complement the spectrum of activity of other quinolones such as norfloxacin and ciprofloxacin, which could be better suited to the treatment of infections occurring in basic pH environ- cemia which bears little resemblance to the type of localized infections usually caused by these organisms in humans. The therapeutic efficacy of E-3846 was studied in the treatment of urinary tract infection in rats, considering the advantages of localized models of chemotherapy (30) . The results of this study demonstrate that orally administered E-3846 is significantly effective in the treatment of cystitis and pyelonephritis caused by important urinary tract pathogens (Table 3 ). E-3846 showed excellent antibacterial activity against Streptococcus faecalis and gram-negative bacteria, such as members of the Enterobacteriaceae, including K. pneumoniae, and also against Pseudomonas aeruginosa. Although E-3646 did not show great activity against K. pneumoniae and Pseudomonas aeruginosa in vitro, it was extremely effective in vivo in eradicating these organisms from the bladder and kidneys. However, despite the enhanced activity of E-3846 against Proteus mirabilis in vitro, its efficacy in vivo was inferior in comparison with its effectiveness against other organisms, possibly because Proteus mirabilis is a ureasplitting organism.
In summary, the potent broad-spectrum activities (especially against gram-positive bacteria) as well as the therapeutic efficacy in treating urinary tract infections and the possibility of using E-3846 in the treatment of other localized and systemic infections make this compound a potentially useful therapeutic agent.
